Emtriva: New Formulation and Labeling Changes
September 28, 2005
On September 28, 2005, The Food and Drug Administration approved EMTRIVA (emtricitabine) Oral Solution 10 mg/mL. The approval of this Oral Solution formulation allows for dosing recommendations in pediatric patients. EMTRIVA is now indicated in combination with other antiretroviral agents, for the treatment of HIV-1 infection in patients over three months of age.
In addition the following changes to the label were made: (Please refer to the attached PDF document for specific details)
Clinical Pharmacology SectionPharmacokinetic data in pediatrics, renal impairment information and results from a drug-drug interaction study with zidovudine were included.
Indications and UsageThe indication was expanded to include patients over three months of age.
PrecautionsAddition of zidovudine to the drug interactions section, addition of the immune reconstitution syndrome section, updated carcinogenicity data and pediatric use statements were included.
Adverse ReactionsThis section was updated to include data in pediatric patients.
Dosage and AdministrationThis section was revised to include dosing information in pediatric patients with the oral solution and capsule formulations. In addition, dosing information for the oral solution for adult patients was included. A new table was added to include dose adjustment information in adults with renal impairment for the capsule and oral solution formulations.
How SuppliedData on storage conditions for the Oral Solution were included.
This article was provided by U.S. Food and Drug Administration. Visit the FDA's website to find out more about their activities and publications.